Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.57+0.07 (+0.67%)
Close on Nov 19, 2026Market cap $8.43BP/E –Yield –
Summit Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Summit Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0. For fiscal 2024 it was $0. The highest annual figure on record is $57.09M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $705.00K | -61.0% |
| FY2021 | Dec 31, 2021 | $1.81M | -96.8% |
| FY2019 | Jan 31, 2019 | $57.09M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $0 | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $220.00K | -83.2% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $235.00K | +312.3% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $250.00K | +30.2% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $251.00K | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $1.31M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $57.00K | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $192.00K | – |
See a number that looks wrong?